Publications by authors named "Maria Serova"

Claim this Profile
G
Glucagon-like Peptide-1 Receptor Agonists in the Context of Pathophysiology of Diverse Heart Failure with Preserved Ejection Fraction Phenotypes: Potential Benefits and Mechanisms of Action.
Aleksandra Bykova, Maria Serova, Maria Chashkina, Raisa Kosharnaya, Zukhra Salpagarova

Card Fail Rev· October 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
BIO101 stimulates myoblast differentiation and improves muscle function in adult and old mice.
Maria Serova, Blaise Didry-Barca, Robin Deloux, Anne-Sophie Foucault, Stanislas Veillet

J Cachexia Sarcopenia Muscle· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
2
20-Hydroxyecdysone activates the protective arm of the RAAS via the MAS receptor.
René Lafont, Maria Serova, Blaise Didry-Barca, Sophie Raynal, Louis Guibout

J Mol Endocrinol· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A new algorithm for optimization of rate-adaptive pacing improves exercise tolerance in patients with HFpEF.
Maria Serova, Denis Andreev, Ilya Giverts, Yulia Sazonova, Aleksey Svet

Pacing Clin Electrophysiol· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Everolimus affects vasculogenic mimicry in renal carcinoma resistant to sunitinib.
Maria Serova, Annemilaï Tijeras-Raballand, Celia Dos Santos, Matthieu Martinet, Cindy Neuzillet

Oncotarget· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of TGF-beta signalling inhibition with galunisertib (LY2157299) in hepatocellular carcinoma models and in ex vivo whole tumor tissue samples from patients.
Maria Serova, Annemilaï Tijeras-Raballand, Célia Dos Santos, Miguel Albuquerque, Valerie Paradis

Oncotarget· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
OTX008, a selective small-molecule inhibitor of galectin-1, downregulates cancer cell proliferation, invasion and tumour angiogenesis.
Lucile Astorgues-Xerri, Maria E Riveiro, Annemilaï Tijeras-Raballand, Maria Serova, Gabriel A Rabinovich

Eur J Cancer· September 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cancer wars: natural products strike back.
Christine Basmadjian, Qian Zhao, Embarek Bentouhami, Amel Djehal, Canan G Nebigil, Maria Serova

Front Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzofuran derivatives as anticancer inhibitors of mTOR signaling.
Christophe Salomé, Nigel Ribeiro, Thierry Chavagnan, Frédéric Thuaud, Maria Serova

Eur J Med Chem· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Unraveling galectin-1 as a novel therapeutic target for cancer.
Lucile Astorgues-Xerri, Maria E Riveiro, Annemilaï Tijeras-Raballand, Maria Serova, Cindy Neuzillet

Cancer Treat Rev· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzofuran derivatives as a novel class of inhibitors of mTOR signaling.
Christophe Salomé, Vanessa Narbonne, Nigel Ribeiro, Frédéric Thuaud, Maria Serova

Eur J Med Chem· March 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
Focus on the role of the CXCL12/CXCR4 chemokine axis in head and neck squamous cell carcinoma.
Sébastien Albert, Maria Eugenia Riveiro, Caroline Halimi, Muriel Hourseau, Anne Couvelard, Maria Serova

Head Neck· December 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benchmarking effects of mTOR, PI3K, and dual PI3K/mTOR inhibitors in hepatocellular and renal cell carcinoma models developing resistance to sunitinib and sorafenib.
Maria Serova, Armand de Gramont, Annemilaï Tijeras-Raballand, Célia Dos Santos, Maria Eugenia Riveiro

Cancer Chemother Pharmacol· May 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive factors of sensitivity to elisidepsin, a novel Kahalalide F-derived marine compound.
Maria Serova, Armand de Gramont, Ivan Bieche, Maria Eugenia Riveiro, Carlos Maria Galmarini

Mar Drugs· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Prognostic value of the chemokine receptor CXCR4 and epithelial-to-mesenchymal transition in patients with squamous cell carcinoma of the mobile tongue.
Sébastien Albert, Muriel Hourseau, Caroline Halimi, Maria Serova, Véronique Descatoire

Oral Oncol· December 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Resistance to targeted therapies in pancreatic neuroendocrine tumors (PNETs): molecular basis, preclinical data, and counteracting strategies.
Annemilaï Tijeras-Raballand, Cindy Neuzillet, Anne Couvelard, Maria Serova, Armand de Gramont

Target Oncol· September 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antitumor agent calixarene 0118 targets human galectin-1 as an allosteric inhibitor of carbohydrate binding.
Ruud P M Dings, Michelle C Miller, Irina Nesmelova, Lucile Astorgues-Xerri, Nigam Kumar, Maria Serova

J Med Chem· June 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Spectrum of cellular responses to pyriplatin, a monofunctional cationic antineoplastic platinum(II) compound, in human cancer cells.
Katherine S Lovejoy, Maria Serova, Ivan Bieche, Shahin Emami, Maurizio D'Incalci

Mol Cancer Ther· September 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Predictive biomarkers for the activity of mammalian target of rapamycin (mTOR) inhibitors.
Catherine Delbaldo, Sébastien Albert, Chantal Dreyer, Marie-Paule Sablin, Maria Serova

Target Oncol· June 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Sébastien Albert, Maria Serova, Chantal Dreyer, Marie-Paule Sablin, Sandrine Faivre

Expert Opin Investig Drugs· August 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial-to-mesenchymal transition and oncogenic Ras expression in resistance to the protein kinase Cbeta inhibitor enzastaurin in colon cancer cells.
Maria Serova, Lucile Astorgues-Xerri, Ivan Bieche, Sebastien Albert, Michel Vidaud

Mol Cancer Ther· May 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Epithelial-to-mesenchymal transition and resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells.
Aïda Ghoul, Maria Serova, Lucile Astorgues-Xerri, Ivan Bieche, Guilhem Bousquet

Cancer Res· May 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antiproliferative effects of rapamycin as a single agent and in combination with carboplatin and paclitaxel in head and neck cancer cell lines.
Nasredine Aissat, Christophe Le Tourneau, Aïda Ghoul, Maria Serova, Ivan Bieche

Cancer Chemother Pharmacol· July 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of protein kinase C modulation by PEP005, a novel ingenol angelate, on mitogen-activated protein kinase and phosphatidylinositol 3-kinase signaling in cancer cells.
Maria Serova, Aïda Ghoul, Karim A Benhadji, Sandrine Faivre, Christophe Le Tourneau

Mol Cancer Ther· April 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Preclinical and clinical development of novel agents that target the protein kinase C family.
Maria Serova, Aïda Ghoul, Karim A Benhadji, Esteban Cvitkovic, Sandrine Faivre

Semin Oncol· August 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis